Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Epigallocatechin-3-gallate (EGCG), the main catechin in green tea, has been investigated for its potential role in supporting or treating psoriasis. The scientific evidence supporting its use is limited but growing, primarily based on preclinical studies. Laboratory research has shown that EGCG possesses anti-inflammatory, antioxidant, and immune-modulating properties. In vitro and animal studies indicate that EGCG can inhibit keratinocyte proliferation and reduce the expression of pro-inflammatory cytokines such as TNF-α and IL-17, which are implicated in the pathogenesis of psoriasis. A few small pilot clinical studies and case reports have explored topical application of green tea extracts or EGCG-containing formulations for psoriasis, showing some reduction in lesion severity and inflammation. However, these studies are limited by small sample sizes, short durations, and lack of standardized formulations.

There is currently insufficient robust clinical evidence to recommend EGCG as a standard treatment for psoriasis. Most findings remain at the preclinical or early clinical stage, and larger, well-designed human trials are needed to confirm safety and efficacy. Nonetheless, the mechanistic rationale is supported by laboratory science, and EGCG is being explored further as a complementary approach. EGCG is not a conventional or traditional remedy for psoriasis, but its use is grounded in emerging scientific evidence rather than historical or anecdotal use.

More about EGCG
More about Psoriasis

Other ingredients used for Psoriasis

Other health conditions supported by EGCG

Products containing EGCG